Should maintenance rituximab be held due to COVID-19 in patients with advanced bulky follicular lymphoma who attain a PR/CR to weekly rituximab?
Answer from: Medical Oncologist at Academic Institution
Yes, hold rituximab. Independent of COVID-19, the RESORT trial demonstrated that retreatment on progression was equivalent to long-term maintenance with less exposure to the drug.
Comments
Medical Oncologist at Genentech I agree with @Andrew D. Zelenetz and would clarify...
I agree with @Andrew D. Zelenetz and would clarify...